Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

CJC-1295 (No DAC) peptide icon, one bubble per amino acidCJC-1295 (No DAC)29 residuesYADAIFTQSYRKVLAQLSARKLLQDILSREach bubble = one amino acid. Size = residue mass. Color = chemical class.

CJC-1295 (No DAC)

Beginner tier: 100 mcg, daily · 12w on / 4w off · community consensus

30 min half-life (estimated)·Injection

Also known as: Mod GRF 1-29, Modified GRF(1-29), GRF(1-29) NH2 (modified)

Zero completed clinical trials for this specific compound, and it's still the most popular GHRH analog in the peptide community. CJC-1295 without DAC (Mod GRF 1-29) is a short-acting growth hormone-releasing hormone analog with a half-life estimated at about 30 minutes. No human study has measured it. It triggers a GH pulse that rises and falls the way your pituitary does on its own, then clears. The 100 mcg dosing convention comes from receptor saturation modeling and community experience across 300 to 600 Reddit threads, not from a clinical trial. Nearly every protocol pairs it with Ipamorelin for a cleaner, stronger pulse.

What Is CJC-1295 (No DAC)?

The community figured this one out before the researchers did. CJC-1295 without DAC, also called Mod GRF 1-29 (parent GRF(1-29) CAS 83930-13-6), is a 29-amino-acid GHRH analog modified at four positions to resist enzymatic breakdown. Its closest human data comes from Corpas et al. (1992)[1], where GHRH(1-29) injected subcutaneously twice daily reversed the low GH and IGF-1 levels of old men.

The mechanism is direct. Mod GRF 1-29 binds the GHRH receptor on pituitary somatotroph cells, triggering a cAMP-driven GH release that peaks around 15 to 30 minutes and clears within the hour. That short action window is the entire point. Unlike the DAC version (which circulates for days and produces tonic GH elevation), the no-DAC form preserves your natural pulsatile rhythm.

Real-world use centers on the Mod GRF + Ipamorelin stack. Community consensus across hundreds of r/Peptides threads and practitioner networks puts the standard protocol at 100 mcg of each, co-injected subcutaneously once or twice daily on a fasted stomach before bed. Users consistently report improved sleep within the first two weeks, faster recovery by week three, and visible body composition changes by month two. Product quality is a known problem; Finnrick Analytics found purity as low as 68.75% across 244 samples from 47 companies. No FDA-approved form exists, and no Phase I, II, or III trial has been completed for Mod GRF 1-29 specifically.

How CJC-1295 (No DAC) Works

Mod GRF 1-29 acts on one receptor, but the downstream cascade is worth understanding. The compound binds to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. This is a Gs protein-coupled receptor. Binding activates adenylyl cyclase, raises intracellular cAMP, and primes the cell for GH synthesis and exocytosis.

Its half-life has never been measured in people; the community estimate is roughly 30 minutes. The closest human data are for a related D-Ala2 analog (Soule et al.)[2]. Given by IV infusion to 10 men, it cleared with a 6.7-minute half-time. Either way, receptor exposure lasts only a brief window. That brevity produces a sharp GH spike that mimics the body's own pulsatile pattern; somatostatin feedback kicks in and shuts the pulse down naturally.

When paired with Ipamorelin (a ghrelin mimetic acting on GHS-R1a), the two pathways converge on the same somatotroph cell from different directions. GHRH sets the amplitude. The ghrelin signal sets the timing. Community reports describe a combined GH pulse larger than either compound alone. Ipamorelin's selectivity matters here. Unlike GHRP-2 or GHRP-6, it doesn't elevate cortisol, ACTH, or prolactin at standard doses. Downstream, the raised GH pulse drives hepatic IGF-1 production, lipolysis through hormone-sensitive lipase activation, and anabolic signaling in muscle and connective tissue.

CJC-1295 (No DAC) Benefits

  • CJC-1295 (No DAC) benefits center on natural GH pulse amplification and the downstream effects that follow.
  • Pulsatile GH release that preserves your body's own feedback loops. Unlike the DAC form or exogenous HGH, somatostatin regulation stays intact (Corpas et al. 1992,; analog mechanism confirmed)[1].
  • Clean hormonal profile when stacked with Ipamorelin. No cortisol, ACTH, or prolactin elevation at 100 mcg doses; this selectivity is what separates the Ipamorelin pairing from GHRP-2 or GHRP-6 stacks (Raun et al. 1998)[3].
  • Improved sleep quality within 1 to 2 weeks. This is the most consistently reported early benefit across community protocols, with users noting deeper sleep and more vivid dreams before any body composition changes appear.
  • Gradual body composition improvement by months 2 to 3. Community reports describe reduced abdominal fat and improved muscle fullness, consistent with GH-mediated lipolysis and anabolic signaling observed in GRF(1-29) infusion literature.
  • Short half-life allows fine-grained protocol control. If side effects appear, the compound clears within hours. Compare that to CJC-1295 DAC, which sustains GH elevation for days after a single injection.

CJC-1295 (No DAC): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 9 key studies·Research only

No dedicated clinical trials exist for the no-DAC / Mod GRF 1-29 form.

Dosing studied: No clinical dose established. Community-derived: 100 mcg per injection (considered functional saturation dose); 1–3 injections per day based on goal.
Read the evidence (key study, limitations)

Mechanism confirmed via GHRH receptor binding analog studies. Human GRF(1-29) infusion data (1990s) confirms pulsatile GH release. The 100 mcg dosing convention is extrapolated from D-Ala2 analog PK studies and community experience, not from a Mod GRF 1-29-specific human trial. The ~30 min half-life is a community estimate; no human study has measured it. Academic research since 2020 has pivoted to higher-potency GHRH analogs; no new no-DAC-specific trial is in progress.

Key Study

Corpas et al. 1992 (PMID 1379256): GHRH(1-29) twice daily reversed the decreased GH and IGF-1 levels in old men; closest proxy for no-DAC human dosing. Soule et al. 1994 (PMID 7962295): D-Ala2-GHRH(1-29)NH2 by IV infusion in 10 men, disappearance half-time 6.7 min vs 4.3 min for GHRH(1-29)NH2; no SC data.

Limitations

Zero completed Phase I/II/III trials for the no-DAC form. Dosing entirely community-derived. The ~30 min half-life is a community estimate: no PK study in humans for this specific compound. No long-term safety data.

Community Experience
Strong
4.0/5
Based on ~300–600+ r/Peptides threads (CJC-1295 / Mod GRF 1-29)

Considered the gold-standard GHRH analog for pulsatile GH release when stacked with Ipamorelin.

Community dosing: 100 mcg per injection, 1–3× daily (fasted)
Read the reports (what users report 5, common issues 5)

Preferred over CJC-1295 DAC for pulse control and avoided GH bleed. Multiple daily injections and strict fasting windows are the main friction points.

What users report (5)
  • Natural pulsatile GH release: physiologically aligned vs. DAC tonic stimulation
  • Clean hormonal profile: no cortisol or prolactin elevation with Ipamorelin pairing
  • Improved sleep quality and depth within weeks 1–2
  • Short half-life allows fine-grained control: easy to stop if side effects emerge
  • Body composition improvement (fat loss, muscle fullness) by months 2–3
Common issues (5)
  • Multiple daily injections required (vs. DAC weekly): common drop-off cause
  • Strict 2-hour fasting window before every injection: non-negotiable for GH pulse
  • Mild water retention (less than DAC but present, especially at higher frequency)
  • IGF-1 often stays near-unchanged without Ipamorelin: solo use discouraged
  • Product quality highly variable; purity as low as 68.75% documented (Finnrick 2024–2026)
Partially Aligned

Science and community agree on GHRH receptor mechanism and pulsatile GH release rationale. Community 100 mcg dosing convention is plausible but not clinically validated for this specific compound: it derives from receptor saturation modeling and analog studies. Science has zero completed trials for the no-DAC form. Fasting requirement is mechanistically sound (insulin raises somatostatin). Cycling rationale is community-derived with no direct clinical confirmation of desensitization at these doses.

CJC-1295 (No DAC) Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner100 mcg
DailyTrack
Moderate100 mcg
2x DailyTrack
Aggressive200 mcg
2x DailyTrack
Note:

Mod GRF 1-29 needs to be co-injected with a GHRP to do much. Solo use rarely moves IGF-1 meaningfully; the community discourages it. Ipamorelin at 100 mcg co-injected is the standard pairing.

Reconstitution math for common vial sizes. A 2 mg vial with 2 mL bacteriostatic water gives you 1,000 mcg/mL. A 100 mcg dose is 10 units on an insulin syringe (0.1 mL). A 5 mg vial with 2 mL bacteriostatic water gives you 2,500 mcg/mL. A 100 mcg dose is 4 units (0.04 mL); a 200 mcg dose is 8 units (0.08 mL).

The fasting window is non-negotiable. Two hours minimum with no food before injection; 30 minutes after. Insulin raises somatostatin, which shuts down the GH pulse completely. This is the number-one troubleshooting issue when users report no IGF-1 movement after weeks on protocol. Check fasting compliance before blaming the peptide.

Abdominal subcutaneous injection absorbs faster than thigh or flank. For a compound with a 30-minute active window, that speed matters.

Cycling Protocol

On Period
12 weeks
Off Period
4 weeks

Cycle to prevent pituitary desensitization. Some users run 5 days on, 2 days off weekly.

Calculate your CJC-1295 (No DAC) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

CJC-1295 (No DAC) Protocols by Goal

beginnerCommunity12 weeks on, 4 weeks off
Induction
Wk 1–2
100 mcg · Once daily (bedtime) · Subcutaneous
Maintenance
Wk 3–12
100 mcg · Once daily (bedtime) · Subcutaneous

Expected: Improved sleep quality within 1–2 weeks; mild recovery improvement by weeks 3–4; modest body composition changes by months 2–3

Monitor: Baseline IGF-1 before starting; recheck at week 6 and week 12. Fasting glucose at baseline.

How to Inject CJC-1295 (No DAC)

  1. 1
    Step 1

    Pull your vial of lyophilized Mod GRF 1-29 from refrigeration (2 to 8 degrees C). Let it reach room temperature for a few minutes. Don't shake it.

  2. 2
    Reconstitute with bacteriostatic water

    For a 2 mg vial, add 2 mL (this gives 1,000 mcg/mL). For a 5 mg vial, add 2 mL (this gives 2,500 mcg/mL). Aim the stream against the glass wall of the vial. Let the powder dissolve; gentle swirling is fine.

  3. 3
    Draw your dose using a 29 to 31 gauge insulin syringe

    For 100 mcg from a 2 mg/2 mL vial, draw to the 10-unit mark (0.1 mL). For 100 mcg from a 5 mg/2 mL vial, draw to the 4-unit mark (0.04 mL). For 200 mcg from a 5 mg/2 mL vial, draw to the 8-unit mark (0.08 mL).

  4. 4
    Step 4

    If stacking with Ipamorelin (recommended), draw both peptides into the same syringe. Order doesn't matter for subcutaneous injection.

  5. 5
    Step 5

    Pinch a fold of skin on the lower abdomen, about 2 inches from the navel. Insert the needle at a 45-degree angle. Inject slowly. Release the skin fold.

  6. 6
    Step 6

    Timing: inject 30 to 60 minutes before bed on a fully fasted stomach (2 or more hours since last food). Don't eat for 30 minutes after injection. An optional second injection can be taken in the morning on waking (fasted) or post-workout (fasted).

  7. 7
    Rotate injection sites each time to prevent lipodystrophy

    Store the reconstituted vial at 2 to 8 degrees C and use within 3 to 4 weeks.

Mixing your own vial? Use the CJC-1295 (No DAC) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

CJC-1295 (No DAC) Stacking Protocols

Works With

Avoid

Sermorelin

Redundant GHRH pathway: both Mod GRF 1-29 and Sermorelin act on the same GHRHR receptor. No additive benefit demonstrated; simply competes at the same binding site. Choose one or the other.

CJC-1295 (DAC)

Combining DAC and no-DAC forms creates overlapping GHRHR stimulation with mismatched half-lives. The DAC form provides sustained tonic GHRH exposure that defeats the pulsatile rationale of no-DAC. No documented benefit; increased receptor desensitization risk.

Exogenous HGH (recombinant GH)

Combining GH secretagogues with exogenous HGH saturates the GH axis and suppresses endogenous pulsatility. Eliminates the primary rationale for using secretagogues (axis preservation). Dramatically increases IGF-1 overshoot risk.

Do not combine

How much does CJC-1295 (No DAC) cost?

Typical price

$6.99 to $9.50 per mg

Typical $8.00

Middle half of 54 US prices for 5 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
Not on the 503A bulks list (21 CFR 216.23); FDA's compounding advisory committee voted against adding it on Dec 4, 2024.

Pricing updated 2026-04-09

CJC-1295 (No DAC) Side Effects

The biggest safety concern with CJC-1295 (No DAC) is that zero completed clinical trials exist for this specific compound. Every side effect profile is extrapolated from analog studies and community experience. That context matters for everything below.

Facial flushing is the most immediately noticeable effect. It typically hits within 5 to 15 minutes of injection, feels like a warm rush to the face and ears, and resolves within 30 to 60 minutes. This is a vasodilatory response from the GH pulse itself, not an allergic reaction. Community reports treat it as a sign the peptide is active. Reducing the dose lessens the intensity.

Headache and dizziness occur in some users, usually during the first week. These tend to be transient and resolve as the body adjusts to regular GH pulses. Injection site redness and irritation are typical of any subcutaneous peptide; rotating sites prevents local tissue issues.

Water retention is the side effect that gets the most community attention at higher dose frequencies. GH promotes sodium and water reabsorption. Mild puffiness around the hands and face is common, especially at twice-daily dosing. If retention becomes pronounced (visible edema, tight rings, swollen ankles), reduce frequency before reducing dose. Persistent edema warrants checking IGF-1 levels.

Carpal tunnel symptoms (tingling, numbness in the hands, grip weakness) signal excessive GH-mediated fluid retention compressing the median nerve. This is a dose-dependent effect. Reduce dose immediately if it appears. If symptoms persist beyond one week at a lower dose, stop entirely and allow four or more weeks of recovery.

GH release antagonizes insulin action. Anyone with diabetes, prediabetes, or insulin resistance should monitor fasting glucose carefully. Teichman et al. (2006)[4] documented insulin sensitivity effects with the DAC form; the no-DAC form carries the same mechanistic risk at lower magnitude due to shorter exposure.

GH promotes cell proliferation. Active cancer or a history of malignancy is a contraindication. Pregnancy and breastfeeding are absolute contraindications. Untreated hypothyroidism can blunt the GH response entirely and should be addressed before starting.

Product quality adds an underappreciated risk layer. Finnrick Analytics tested 244 samples from 47 companies and found purity ranging from 68.75% to 99.95%. Underdosed or degraded product produces unpredictable responses; the no-DAC form (MW approximately 3,367 Da) is sometimes substituted with the DAC form (MW approximately 3,647 Da) in low-quality products.

When to see a doctor: carpal tunnel symptoms that don't resolve with dose reduction, persistent unexplained edema, fasting glucose above 125 mg/dL, or any new numbness or paresthesia.

Common Issues & Solutions

No IGF-1 change after 8 weeks: Most common cause is eating within 2 hours before injection: insulin raises somatostatin and blunts the GH pulse completely. Check fasting compliance first, then product quality (a batch-specific CoA is the only check).

Facial flushing within minutes of injection: Expected vasodilatory response from GH release. Usually peaks at 5–15 minutes, resolves within 30–60 minutes. Reduce dose if severe; does not indicate an allergic reaction in most cases.

Water retention / puffiness: Common with any GH secretagogue. Reduce injection frequency before reducing dose. If significant edema persists, stop and check IGF-1 levels: may indicate excessive GH response.

Diminishing response after week 8–10: Consistent with somatostatin tone accumulation and possible GHS-R1a desensitization (from Ipamorelin component). Consider cycling off 2 weeks early rather than pushing through. Ensure 4-week off period before restarting.

Tingling or numbness in hands: Early carpal tunnel symptom from GH-mediated fluid retention. Reduce dose or frequency immediately. If it persists more than 1 week at reduced dose, discontinue and allow 4+ weeks recovery.

Ask AI about this page

Ask AI for a second opinion on CJC-1295 (No DAC) dosing and side effects

Contraindications

  • Active cancer or history of malignancy: GH promotes cell proliferation
  • Diabetes mellitus: GH antagonizes insulin and may worsen blood sugar control
  • Pregnancy or breastfeeding
  • Active pituitary tumors or intracranial neoplasms
  • Known hypersensitivity to GHRH analogs
  • Untreated hypothyroidism: may blunt GH response

Drug Interactions

  • Insulin and oral hypoglycemics: GH release antagonizes insulin action; monitor blood glucose closely
  • Corticosteroids: chronic use may blunt GH response and reduce efficacy
  • Other GH secretagogues (GHRP-2, GHRP-6, Ipamorelin): additive GH release increases side effect risk; use caution when stacking
  • Thyroid hormones: GH can accelerate T4-to-T3 conversion; monitor thyroid function
  • CYP3A4-metabolized drugs: GH may alter hepatic clearance rates
  • Redundant GHRH pathway: both Mod GRF 1-29 and Sermorelin act on the same GHRHR receptor. No additive benefit demonstrated; simply competes at the same binding site. Choose one or the other.
  • Combining DAC and no-DAC forms creates overlapping GHRHR stimulation with mismatched half-lives. The DAC form provides sustained tonic GHRH exposure that defeats the pulsatile rationale of no-DAC. No documented benefit; increased receptor desensitization risk.

Product Quality

Recommended Monitoring

TestWhenTarget
IGF-1Baseline before starting; repeat at week 6 and week 12Age-adjusted normal range (not supraphysiological). Flag if above upper limit of normal.
IGFBP-3Baseline; repeat at week 12Age-adjusted normal range
Fasting glucoseBaseline; repeat at week 6 and week 12<100 mg/dL (normal); 100–125 mg/dL warrants dose reduction and closer monitoring
Thyroid (TSH, fT3, fT4)Baseline; repeat at week 12 if symptoms emergeNot listed
IGF-1

Primary efficacy marker for GH axis activation. Confirms peptide quality and dosing adequacy. Detects over-response requiring dose reduction.

IGFBP-3

Low IGFBP-3 with elevated IGF-1 = elevated free IGF-1 → increased cancer signaling risk. IGF-1 alone is insufficient for safe GH axis monitoring.

Fasting glucose

GH release antagonizes insulin action. Relevant especially in pre-diabetic or insulin-resistant individuals.

Thyroid (TSH, fT3, fT4)

GH accelerates T4-to-T3 conversion. Untreated hypothyroidism blunts GH response; GH supplementation can unmask subclinical hypothyroidism.

CJC-1295 (No DAC) Before and After

Week 1-2

Improved sleep quality and more vivid dreams. Some users report mild water retention and occasional facial flushing after injection.

Weeks 3-4

Noticeable improvements in recovery time between workouts. Skin hydration and texture begin to improve. Increased morning energy.

Months 2-3

Body composition shifts become apparent: reduced abdominal fat and improved muscle tone. Joint and connective tissue comfort improves.

Months 3-4

Full anti-aging and recovery benefits are established. Sustained fat loss, better exercise capacity, and improved skin elasticity.

Month 5+

Benefits plateau at this stage. Cycle off for 4 weeks to maintain pituitary receptor sensitivity before restarting protocol.

What to Expect

Week 1 to 2: Sleep changes come first. Most users report deeper sleep and more vivid dreams within the first week of consistent bedtime dosing. Mild facial flushing after injection is normal and resolves in under an hour. Some water retention appears early on.

Weeks 3 to 6: Recovery speed improves. Muscle soreness between workouts decreases noticeably. Skin hydration gets better. IGF-1 should be measurably raised by week 4 if fasting compliance is strict and product quality is good. Energy tends to pick up through this stretch.

Weeks 6 to 12: Body composition shifts become visible. Reduced abdominal fat and improved muscle fullness are the most commonly reported changes in this window. Skin elasticity improves. Joint comfort gets better. Some users plateau around week 10 to 12 as somatostatin tone accumulates and receptor sensitivity declines.

Month 4 and beyond (off cycle): The compound clears within hours of the last injection; no GH bleed like the DAC form. Pituitary receptor sensitivity recovers within 2 to 4 weeks. Benefits are largely retained for 4 to 6 weeks post-cycle. Body composition regresses gradually over 6 to 8 weeks without the protocol. Most users restart after the standard 4-week off period.

Detailed Timeline: Science vs Community

Week 1–2
Science

GH pulse augmentation confirmed immediately in analog studies; IGF-1 elevation begins within days of consistent dosing.

Community

Improved sleep quality and more vivid dreams are the first-reported effects. Some users note mild facial flushing post-injection and mild water retention.

Weeks 3–6
Science

IGF-1 should be measurably elevated by week 4 with consistent protocol. GH promotes anabolic signaling in connective tissue.

Community

Faster workout recovery, reduced muscle soreness, improved skin hydration. Early lean tissue quality improvement noted. Energy generally improves.

Weeks 6–12
Science

GH/IGF-1 axis-mediated lipolysis and anabolic signaling produce measurable body composition changes over 8–12 weeks in GRF(1-29) infusion literature.

Community

Visible reduction in abdominal fat, improved muscle fullness, better skin elasticity. Joint and connective tissue improvement. Some users plateau at week 10–12.

Month 4+ (off cycle)
Science

Short half-life (~30 min, estimated) means compound clears within hours of last injection. No prolonged GH bleed unlike CJC-1295 DAC. Pituitary receptor sensitivity should recover within 2–4 weeks off.

Community

Benefits largely retained for 4–6 weeks post-cycle. Some regression in body composition over 6–8 weeks without protocol. Most users restart after the 4-week off period.

Pharmacokinetics

Half-Life
30min
Bioavailability
SC: not measured in humans
Tmax
5-15 minutes (peak GH pulse occurs 15-30 min post-injection)
Data Confidence
low

Source: No human PK study of Mod GRF 1-29; ~30 min is a community estimate. Closest measured analog: D-Ala2-GHRH(1-29)NH2, 6.7 min disappearance half-time during IV infusion in 10 men (Soule et al. 1994, PMID 7962295)

Pharmacokinetics: Active Dose Over Time

t½ = ~30 min (estimated, never measured in humans)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
29
Molecular Weight
3,367.95 Da
Sequence
YADAIFTQSYRKVLAQLSARKLLQDILSR
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 863288-34-0

Who Should Consider CJC-1295 (No DAC)

  • Adults over 30 experiencing age-related GH decline (somatopause)
  • Athletes and bodybuilders seeking improved recovery and body composition
  • Individuals looking to improve sleep quality and depth
  • Post-injury patients wanting faster tissue repair
  • Those who prefer natural pulsatile GH release over sustained elevation

Related Peptides

What Changed for CJC-1295 (No DAC)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]GH-Releasing Hormone-(1-29) Twice Daily Reverses Decreased GH and IGF-I Levels in Old Men (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Incorporation of D-Ala2 in GHRH-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men (Soule et al., J Clin Endocrinol Metab 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Ipamorelin, the first selective growth hormone secretagogue (Raun et al. 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy Adults (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Advances in the detection of growth hormone releasing hormone synthetic analogs (Memdouh et al., Drug Test Anal 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry (J Pharm Biomed Anal 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C, stable up to 12 months
After Reconstitution
Refrigerate, use within 3-4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

The pituitary requires ~3+ hours between stimulations for meaningful recovery. If three daily doses are spaced at least 3 hours apart, each should produce a GH pulse. Community reports suggest diminishing returns on the third daily injection, possibly because somatostatin feedback accumulates through the day. No clinical data exists for the no-DAC form specifically.

Most common causes in order: eating within 2 hours of injection (completely blunts the GH pulse), degraded or underdosed peptide (only a CoA can rule this out), individual baseline IGF-1 already near the ceiling for your age, or insufficient dose frequency. Troubleshoot fasting first, then product quality.

No pharmacokinetic interactions with exogenous testosterone are established. The practical concern is combined IGF-1 + testosterone anabolic signaling, which may require more careful IGF-1 monitoring. No clinical trial data covers this combination.

GHRH secretagogues are broadly considered more axis-friendly than direct HGH injections because they preserve GH feedback loops; somatostatin still responds, keeping regulation in place. However, chronic daily use can alter pulsatile patterns and potentially shift somatostatin tone. There is no definitive clinical answer for the no-DAC version.

Abdominal subcutaneous injection typically has faster absorption than thigh or flank, which is preferable for a compound with a ~30-minute active window. Community consensus favors abdominal SC injection for both Mod GRF and Ipamorelin. No clinical comparison of injection sites exists for this compound.